Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.H.C. Wainwright BioConnect 2021 Conference Date:January 11, 2021 What:Lumos Pharma Presentation A webcast of Lumos Pharma’s presentation will be available on-demand as of 6:00AM ET, Mo...
If you want to know who really controls Lumos Pharma, Inc. ( NASDAQ:LUMO ), then you'll have to look at the makeup of...
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]
AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in December: Piper Sandler Healthcare Conference Date:Monday, November 23, 2020 What:Fireside chat with Lumos Pharma management Management will host virtual one-on-one meetings durin...
* Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ended September 30, 2020 and provided an update on clinical activities.“This past quarter was marke...
NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Lumos Pharma Inc (NASDAQ:LUMO) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 10, 2020 at 4:30 PM Eastern Time.